Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

We expected miracles—what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A doctor has issued an warning as to why Ozempic shouldn't be used for weight loss as it does one alarming thing to body.

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but is coming under competitive pressure ...

A man is suing the manufacturers of Ozempic, alleging the diabetes drug caused him to go blind. The medication, containing semaglutide, works by regulating blood sugar and suppressing hunger. While ...